Gold prices bounce off 3-week lows; demand likely longer term
BeiGene (NASDAQ:ONC), Ltd. (NASDAQ:BGNE), a global biotechnology company headquartered in the Cayman Islands, held its Annual Meeting of Shareholders on May 21, 2025. The company, which specializes in pharmaceutical preparations, announced the results of the shareholder vote in a recent 8-K filing with the U.S. Securities and Exchange Commission.
The shareholders voted on several key resolutions, including the re-election of Class III directors Mr. Anthony C. Hooper, Mr. Ranjeev Krishana, Dr. Xiaodong Wang, and Mr. Qingqing Yi, who will serve until the 2028 annual general meeting. Additionally, Ms. Shalini Sharp (OTC:SHCAY) was re-elected as a Class II director until the 2027 annual general meeting. The terms of other directors, including Dr. Olivier Brandicourt, Dr. Margaret Dugan, Mr. Michael Goller, Mr. John V. Oyler, Dr. Alessandro Riva, and Dr. Corazon (Corsee) D. Sanders, continued after the meeting.
The shareholders also ratified the selection of Ernst & Young LLP, Ernst & Young, and Ernst & Young Hua Ming LLP as the company’s independent auditors for the fiscal year ending December 31, 2025. The Board of Directors was authorized to fix the auditors’ compensation.
Furthermore, the shareholders approved the General Mandate to Issue Shares, allowing the Board to issue, allot, or deal with unissued shares not exceeding 20% of the total number of issued shares. The General Mandate to Repurchase Shares was also approved, permitting the Board to repurchase up to 10% of the total number of issued shares.
A notable resolution was the Connected Person Placing Authorization, which authorizes the allocation of shares to Amgen Inc (NASDAQ:AMGN). to maintain its shareholding percentage in the event of an offering.
Additionally, on a non-binding, advisory basis, the compensation of the company’s named executive officers was approved. Lastly, the shareholders agreed to authorize the adjournment of the Annual Meeting by the chairman to solicit additional proxies if necessary.
The filing, signed by Senior Vice President and General Counsel Chan Lee, confirms the outcomes of the votes and demonstrates BeiGene’s commitment to corporate governance and shareholder engagement. The detailed voting results for each resolution were provided, reflecting transparency in the company’s decision-making process.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.